LYSA DEL GROSSO: Open Payments
NPI 1578089215 · LEXINGTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,110 in 121 payments from 11 companies in 2025. Trend: 2023 $2,088 · 2024 $2,159 · 2025 $2,110
Food & beverage: $2,110
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $424 |
| Neurocrine BioSciences, Inc. | 22 | $404 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $290 |
| E.R. Squibb & Sons, L.L.C. | 12 | $239 |
| Teva Pharmaceuticals USA, Inc. | 17 | $216 |
| Janssen Pharmaceuticals, Inc | 3 | $197 |
| Alkermes, Inc. | 10 | $154 |
| Otsuka America Pharmaceutical, Inc. | 7 | $137 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, COBENFY, INVEGA SUSTENNA, UZEDY, ARISTADA, REXULTI.
Industry payments across SC — which companies pay providers there.
